Journal of Parkinson’s Disease welcomes new co-Editor-in-Chief Lorraine V. Kalia, MD, PhD, FRCPC

Associate Professor and Clinician Scientist

Amsterdam, May 20, 2022 – The Journal of Parkinson’s Disease (JPD), published by IOS Press, is pleased to announce the appointment of new co-Editor-in-Chief, Lorraine V. Kalia, MD, PhD, FRCPC. Dr. Kalia joins co-Editor-in-Chief Bas Bloem, MD, PhD, FRCPE, and an eminent international editorial board, who are dedicated to the continuing success of the world’s leading journal in Parkinson’s research.

Credit: Lorraine V. Kalia, MD, PhD, FRCPC

Amsterdam, May 20, 2022 – The Journal of Parkinson’s Disease (JPD), published by IOS Press, is pleased to announce the appointment of new co-Editor-in-Chief, Lorraine V. Kalia, MD, PhD, FRCPC. Dr. Kalia joins co-Editor-in-Chief Bas Bloem, MD, PhD, FRCPE, and an eminent international editorial board, who are dedicated to the continuing success of the world’s leading journal in Parkinson’s research.

A globally recognized authority on Parkinson’s disease, Lorraine V. Kalia, MD, PhD, FRCPC, is an Associate Professor and Clinician Scientist in the Division of Neurology at the University of Toronto and a Senior Scientist at the Krembil Research Institute of the University Health Network. She holds appointments with the University of Toronto’s Tanz Centre for Research in Neurodegenerative Diseases and Department of Laboratory Medicine and Pathobiology. She is also a Staff Neurologist in the Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson’s Disease at the Toronto Western Hospital, University Health Network.

Dr. Kalia serves as Co-Chair of the Scientific Issues Committee and a Steering Committee Member of the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society. Her clinical work and research program focus on Parkinson’s disease and related movement disorders. With an eye always on the clinic, she heads a research team focused on elucidating the critical molecular mechanisms responsible for neurodegeneration in Parkinson’s disease and identifying therapeutic agents that can target these molecular mediators of neurodegeneration.

Dr. Kalia’s appointment follows the departure of one of JPD’s founding editors, Patrik Brundin, MD, PhD, who has moved out of academia and is now Therapeutic Area Leader for Movement Disorders at Roche Pharmaceutical Research and Early Development. Dr. Brundin served as co-Editor-in-Chief for 12 years, from its days as a fledging journal to its current position as a leading publisher of groundbreaking Parkinson’s research. He looks forward to seeing the journal’s continued growth and success.

Dr. Kalia commented, “I am excited to be stepping into the role of co-Editor-in-Chief, although I appreciate that Patrik’s shoes are very large ones to fill. Bas and Patrik have done incredible work for the journal, increasing its reach and impact over the past few years. I look forward to working with Bas and the team to maintain this positive trajectory by further developing the journal as a unique open forum for excellent research into Parkinson’s that also includes the voice of those affected by the disease.”

“I could not be more thrilled that Lorraine Kalia has consented to join JPD as the new co-Editor-in-Chief,” added Dr. Bloem, Radboud University Nijmegen Medical Centre. “Dr. Kalia has an outstanding track record in the field of Parkinson research, and she is a wonderful colleague to work with. She and I are already working on plans to take our journal to the next level, so please stay tuned for more information soon!”


You May Also Like